Skip to main content
Top
Published in: International Journal of Hematology 3/2008

01-10-2008 | Original Article

CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy

Authors: Kazue Watanabe, Susumu Suzuki, Michi Kamei, Shingo Toji, Takakazu Kawase, Toshitada Takahashi, Kiyotaka Kuzushima, Yoshiki Akatsuka

Published in: International Journal of Hematology | Issue 3/2008

Login to get access

Abstract

The efficient isolation and ex vivo expansion of antigen-specific T cells are crucial for successful adoptive immunotherapy against uncontrollable infections and cancers. Several methods have been reported for this purpose, for example, employing MHC-multimeric complexes, interferon-gamma secretion, and antibodies specific for molecules expressed on T-cell surfaces, including CD25, CD69, CD107a, CD137, and CD154. Of the latter, CD137 has been shown to be one of the most promising targets since it is only expressed on CD8+ T cells early after encountering antigen, while being almost undetectable on resting cells. However, detailed comparisons between CD137-based and other methods have not yet been conducted. In this study, we therefore compared three approaches (with CD137, CD107a, and tetramers) using HLA-A24-restricted CMV pp65 and EBV BRLF1 epitopes as model antigens. We found that the CD137-based isolation of antigen-stimulated CD8+ T cells was comparable to tetramer-based sorting in terms of purity and superior to the other two methods in terms of subsequent cell expansion. The method was less applicable to CD4+ T cells since their CD137 upregulation is not sufficiently high. Collectively, this approach is most likely to be optimal among the methods tested for the isolation and expansion of antigen-specific CD8+ cells.
Literature
1.
go back to reference Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation—challenging the status quo. Clin Transplant. 2007;21:149–58.CrossRefPubMed Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation—challenging the status quo. Clin Transplant. 2007;21:149–58.CrossRefPubMed
2.
go back to reference Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003;17:417–22.CrossRefPubMed Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003;17:417–22.CrossRefPubMed
3.
go back to reference Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1–10.CrossRefPubMed Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1–10.CrossRefPubMed
4.
go back to reference Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038–44.CrossRefPubMed Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038–44.CrossRefPubMed
5.
go back to reference Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–5.CrossRefPubMed Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–5.CrossRefPubMed
6.
go back to reference Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059–66.CrossRefPubMed Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059–66.CrossRefPubMed
7.
go back to reference Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.CrossRefPubMed Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.CrossRefPubMed
8.
go back to reference Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant. 2006;12:9–12.CrossRefPubMed Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant. 2006;12:9–12.CrossRefPubMed
9.
go back to reference Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377–82.CrossRefPubMed Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377–82.CrossRefPubMed
10.
go back to reference Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65–78.CrossRefPubMed Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65–78.CrossRefPubMed
11.
go back to reference Brosterhus H, Brings S, Leyendeckers H, et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol. 1999;29:4053–9.CrossRefPubMed Brosterhus H, Brings S, Leyendeckers H, et al. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol. 1999;29:4053–9.CrossRefPubMed
12.
go back to reference Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201–10.CrossRefPubMedPubMedCentral Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201–10.CrossRefPubMedPubMedCentral
13.
go back to reference Baumann S, Krueger A, Kirchhoff S, Krammer PH. Regulation of T cell apoptosis during the immune response. Curr Mol Med. 2002;2:257–72.CrossRefPubMed Baumann S, Krueger A, Kirchhoff S, Krammer PH. Regulation of T cell apoptosis during the immune response. Curr Mol Med. 2002;2:257–72.CrossRefPubMed
14.
go back to reference Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68.CrossRefPubMed Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68.CrossRefPubMed
15.
go back to reference Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168:4897–906.CrossRefPubMed Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168:4897–906.CrossRefPubMed
16.
go back to reference Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood. 2007;109:365–73.CrossRefPubMed Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood. 2007;109:365–73.CrossRefPubMed
17.
go back to reference Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005;11:1118–24.CrossRefPubMed Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005;11:1118–24.CrossRefPubMed
18.
go back to reference Sabbagh L, Kaech SM, Bourbonniere M, et al. The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol. 2004;173:5425–33.CrossRefPubMed Sabbagh L, Kaech SM, Bourbonniere M, et al. The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol. 2004;173:5425–33.CrossRefPubMed
19.
go back to reference Burrows SR, Suhrbier A, Khanna R, Moss DJ. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell–T-cell killing. Immunology. 1992;76:174–5.PubMedPubMedCentral Burrows SR, Suhrbier A, Khanna R, Moss DJ. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell–T-cell killing. Immunology. 1992;76:174–5.PubMedPubMedCentral
20.
go back to reference Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616–26.CrossRefPubMedPubMedCentral Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616–26.CrossRefPubMedPubMedCentral
21.
go back to reference Diab A, Cohen AD, Alpdogan O, Perales MA. IL-15: targeting CD8+ T cells for immunotherapy. Cytotherapy. 2005;7:23–35.CrossRefPubMed Diab A, Cohen AD, Alpdogan O, Perales MA. IL-15: targeting CD8+ T cells for immunotherapy. Cytotherapy. 2005;7:23–35.CrossRefPubMed
Metadata
Title
CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy
Authors
Kazue Watanabe
Susumu Suzuki
Michi Kamei
Shingo Toji
Takakazu Kawase
Toshitada Takahashi
Kiyotaka Kuzushima
Yoshiki Akatsuka
Publication date
01-10-2008
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0134-z

Other articles of this Issue 3/2008

International Journal of Hematology 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine